SCHEDULE: Blue Owl Capital Holdings LP Discloses Stake in ImageneBio

Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, reporting beneficial ownership of 959,337 shares of ImageneBio, Inc. common stock, representing 8.51% of the class.

Summary

• Blue Owl Capital Holdings LP has amended its Schedule 13G filing concerning ImageneBio, Inc.
• The filing indicates that Blue Owl Capital Holdings LP beneficially owns 959,337 shares of ImageneBio, Inc. common stock.
• This ownership represents 8.51% of the total class of common stock outstanding.
• The percentage is calculated based on 11,279,130 shares of Common Stock outstanding as of April 30, 2026, as reported in ImageneBio's 10-Q filed on May 7, 2026.
• Blue Owl Capital Holdings LP is organized in Delaware.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of ownership and does not provide new operational or financial performance data for ImageneBio, Inc. itself.

Positives

• Blue Owl Capital Holdings LP has disclosed a significant ownership stake of 8.51% in ImageneBio, Inc., which could signal confidence in the company's future prospects.
• The reporting person is a recognized investment entity, suggesting a strategic investment rather than a passive one.

Negatives

• The filing is an amendment to a Schedule 13G, which typically indicates a change in ownership or a correction, but the specific reason for the amendment is not detailed beyond reporting the current stake.

Risks

• The filing does not explicitly mention any risks. However, any investment carries inherent market risks associated with the biotechnology sector and the specific performance of ImageneBio, Inc.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from ImageneBio, Inc. It is a disclosure of ownership by Blue Owl Capital Holdings LP.

Management Comments

• "The reported percentage is calculated based on 11,279,130 shares of Common Stock outstanding as of April 30, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on May 7, 2026."
• "Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake disclosures by institutional investors like Blue Owl Capital Holdings LP in biotechnology companies can often precede major corporate events or signal strong conviction in a company's technology or market position. The biotechnology sector is highly dynamic, with substantial capital often required for research and development, making institutional backing crucial.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable investor like Blue Owl Capital Holdings LP may be viewed positively, potentially increasing investor confidence. However, it does not directly impact current operations or immediate shareholder returns.
• Creditors: No direct impact is indicated.
• Employees: No direct impact is indicated.
• Suppliers: No direct impact is indicated.
• Customers: No direct impact is indicated.

Next Steps

• Blue Owl Capital Holdings LP will continue to monitor its investment in ImageneBio, Inc.
• ImageneBio, Inc. will continue its operations and reporting as per SEC regulations.

Key Dates

Keywords

Schedule 13G, Blue Owl Capital Holdings LP, ImageneBio, Inc., Beneficial Ownership, Common Stock, Investment, SEC Filing, Biotechnology